Martin David Harp

The resubmission follows a successful appeal by the company with the Office of New Drugs (OND).

Ultra-widefield pediatric retinal scans plus adaptable AI reveal hidden eye issues during routine visits, enabling comfortable, scalable screening and earlier specialist referrals.

Caveolin‑1 is a membrane-associated protein expressed in many cell types that plays a key role in modulating inflammatory signaling.

Jay Chhablani, MD, a retina specialist from UPMC Vision Institute and director of the Choroidal Analysis and Research Lab at the University of Pittsburgh, discussed recent advancements in choroidal imaging.

Uveitis expert Nisha Acharya, recipient of ARVO’s Mildred Weisenfeld Award, discusses how clinical trials and big data are reshaping treatment, vaccination, and vision outcomes.

Paul Nderitu discusses Global RETFound, a diverse, worldwide retinal AI model that outperforms existing tools and sets a new standard for equitable, open-access medical AI.

NYU researchers discuss using CellChek C widefield specular microscopy to visualize and quantify corneal nerves in dry eye disease, revealing reduced nerve fiber length and inferior whorl changes and offering a practical alternative to in vivo confocal imaging.

At ARVO Michael Siatkowski, MD, and Jody Summers, PhD, stopped to discuss the rising rates of myopia in children and if anti-inflammatory drugs could play a role in slowing progression.

Single-shot optogenetic injection restores light sensitivity in advanced retinitis pigmentosa, delivering sustained vision gains for years with strong safety, expanding hope beyond gene-specific therapy.

At ARVO 2026, Michael Ip, MD, presented findings from a large-scale analysis of OCT biomarkers in patients with diabetic macular edema (DME), leveraging the robust DRCR Retina Network Protocol T dataset.

Aaron Lee, MD, and Cecilia Lee, MD, co-recipients of this year's Cogan Award at ARVO, reflect on what the award lecture means to them and their careers.

Dimitra Skondra, MD, PhD, discussed her talk on how the diet and gut microbiome can affect the development of age-related macular degeneration.

AI-assisted screening in glaucoma clinics flags patient distress early, improving adherence and outcomes without adding staff burden.

Ariel Ong, a fellow from University College London, discussed her ARVO poster, looking at her work on developing a scalable pipeline for data extraction from ophthalmic clinical letters and what significance that could have in managing patients.

Madhura Tamhankar, MD, took some time at the ARVO conference in Denver, Colorado, to discuss a poster on disease progression in thyroid eye disease, stressing what we know about the Rundle Curve may not be accurate.

The poster looked into the LLM's potential for biases in gender and race when it came to its knowledge of retinitis pigmentosa.

Srinivas Sadda, MD, FARVO, immediate past president of ARVO, discusses the impact the organization has had on his career and how he wants to help the next generation.

Kaden Bunch, a fourth-year medical student from the Warren Alpert Medical School of Brown University, talked about his poster on large language models and the effectiveness of diagnosing red eye diseases.

At this year's ARVO meeting in Denver, Colorado, Giulia Corradetti spoke on how baseline OCT biomarkers can predict anatomic response in neovascular age-related macular degeneration when treated with faricimab.

The trial will evaluate EC-104 fluocinolone acetonide (FA) extended release for the treatment of diabetic macular edema (DME).

Immunovant, along with partner HanAll, will assess future plans for the development of batoclimab and provide an update at a future, unspecified date

MALBEC (NCT07440225) is a randomized, double-masked trial evaluating the safety and efficacy of MK-8748 at 2 dose levels versus control (aflibercept 2mg).

Regeneron announced that the FDA has amended the EYLEA HD label after the approval, adding 96-week results from the PULSAR wAMD trial and the PHOTON DME trial.

The merger, originally announced in March 2025, included the ALLY Robotic Cataract Laser Treatment System.

QoL areas measured included enjoying relationships/life, overall mood, and time spent thinking of eye pain.

Previously, the company had received CRLs from the FDA in April 2025 and November 2023 for NDAs for reproxalap for the treatment of dry eye.

See which ophthalmology surgery centers earn US News’ 2026 high-performing badge, where they cluster, and why complication rates drop 40%.

The BIM-IOL System consists of 2 non-bioerodible drug pads attached to the optic-haptic junction of a monofocal intraocular lens (IOL), which is implanted as part of routine cataract surgery.

The phase 2a study looks at retinal vascular diseases, including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO).

The planned phase 3 trial will evaluate the triamcinolone acetonide injectable for managing inflammation and pain after cataract surgery.